ResMed (RMD) Tops Q2 EPS by 5c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
JPMorgan Downgrades ResMed (RMD:AU) (RMD) to Underweight
January 25, 2019 7:10 AM ESTJPMorgan analyst David Low downgraded ResMed (RMD:AU) (NYSE: RMD) from Neutral to Underweight with a price target of AUD13.40.
Low notes results were boosted by a one-off benefit. Sales will likely be subdued over much of 2019 as the business cycles... More
Goldman Sachs Downgrades ResMed (RMD:AU) (RMD) to Neutral
January 25, 2019 7:01 AM ESTGoldman Sachs analyst Chris Cooper downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy to Neutral with a price target of AUD15.20 (from AUD16.70).
Cooper said shares were priced for perfection going into the 2Q print and the company delivered a meaningful 3% sales... More
Deutsche Bank Downgrades ResMed (RMD) to Hold
January 23, 2019 8:42 AM ESTDeutsche Bank downgraded ResMed (NYSE: RMD) from Buy to Hold.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $117.69 yesterday.
... More